Mizuho Markets Americas LLC Trims Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Mizuho Markets Americas LLC cut its Kenvue stake by 85% in the first quarter, selling about 12.0 million shares and leaving it with 2.1 million shares worth roughly $36.6 million.
• Kenvue reported better-than-expected quarterly results, posting EPS of $0.32 versus $0.27 expected and revenue of $3.91 billion, up 4.5% year over year.
• Analysts remain cautious overall: the stock has a Hold consensus rating with a $19.58 average price target, while Kenvue also pays a quarterly dividend of $0.2075, yielding about 4.4%.

Mizuho Markets Americas LLC lowered its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 85.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,123,921 shares of the company's stock after selling 12,030,014 shares during the period. Kenvue accounts for approximately 1.0% of Mizuho Markets Americas LLC's portfolio, making the stock its 28th biggest holding. Mizuho Markets Americas LLC owned 0.11% of Kenvue worth $36,616,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new position in Kenvue in the 4th quarter valued at about $26,000. Physician Wealth Advisors Inc. grew its holdings in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after buying an additional 618 shares in the last quarter. MV Capital Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth about $28,000. Reflection Asset Management acquired a new position in shares of Kenvue in the fourth quarter valued at approximately $32,000. Finally, SBI Securities Co. Ltd. raised its position in shares of Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company's stock valued at $39,000 after buying an additional 1,027 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

KVUE stock opened at $18.89 on Friday. The company has a market cap of $36.28 billion, a PE ratio of 22.23, a price-to-earnings-growth ratio of 1.45 and a beta of 0.47. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $18.33 and a two-hundred day moving average price of $17.91. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $22.87.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.24 EPS. As a group, research analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.4%. Kenvue's dividend payout ratio (DPR) is presently 97.65%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on KVUE shares. Citigroup decreased their target price on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 15th. Wall Street Zen raised Kenvue to a "buy" rating in a research note on Sunday, July 12th. UBS Group raised their price objective on Kenvue from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Thursday, July 16th. Barclays lifted their price objective on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday. Finally, Zacks Research lowered Kenvue from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $19.58.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 1.59% of the company's stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.